



May 12, 2025

Company: KYORIN Pharmaceutical Co., Ltd.
Representative: Yutaka Ogihara
Representative Director, President and CEO
(Security Code: 4569, TSE Prime.)
Contact: Shota Kikuchi
Director, Corporate Planning
Telephone: 03-6374-9702

Notice Regarding Revision to Annual Dividend Forecast (Special Dividend)

KYORIN Pharmaceutical Co., Ltd. (the “Company”) announced today that, at the Board of Directors meeting held on May 12, 2025, it has resolved to implement a special dividend for the fiscal year ending March 31, 2025. It is hereby noted that the aforementioned matter is scheduled for determination at the Board of Directors meeting held on May 21, 2025.

1. Annual dividend

	Annual dividend per share		
	Interim	Fiscal year-end	Total
Previous forecast	—	32.00	52.00
Revised forecast	—	37.00 (Ordinary dividend 32.00) (Special dividend 5.00)	57.00 (Ordinary dividend 52.00) (Special dividend 5.00)
Result for fiscal year ended March 31, 2025	20.00	—	—
Result for fiscal year ended March 31, 2024	20.00	32.00	52.00

2. Reason of revision

Company’s financial strategy aims to increase capital efficiency through investments for growth and shareholder returns, with a constant awareness of the cost of capital and return on capital, maintaining a sound financial base. Regarding shareholder returns, Company is committed to providing stable dividends in consideration the dividend on equity (DOE) ratio.

Given the significant year-on-year increase in profit for the fiscal year ended March 31, 2025, and after comprehensive consideration of its financial condition and other factors, Company has resolved to implement a special dividend of 5.00 JPY per share for the fiscal year ended March 31, 2025.

Consequently, the year-end dividend for the fiscal year ended March 31, 2025, will be 37.00 JPY per share, comprising the ordinary dividend of 32.00 JPY per share and the special dividend of 5.00 JPY per share. The total annual dividend for the fiscal year ended March 31, 2025, will be 57.00 JPY.

This document is for reference purposes only. In case of any discrepancy, the Japanese version shall prevail.